Sarepta Therapeutics Inc. (NASDAQ:SRPT) currently has a daily average trading volume of 1.22M but it saw 1755677 shares traded on Thursday. With a market cap of 13.58B USD, stock’s current market price of $149.67 came rising about 2.89 while comparing to the previous closing price of $145.47. In past 52 weeks, the stock remained buoying in the range of price level as high as $159.84 and as low as $61.28. In the recent trading on the day, stock has struck highest price mark of $150.805 while lowest mark touched by it was $143.75.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Taking a look at 20-day trading activity of Sarepta Therapeutics Inc. (SRPT) gives us an average price of $138.86, while its current price level is -6.36% below from 52-week high level whereas it is 144.24% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $129.39 while that of 200 days or SMA-200 reads an average of $109.52. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.04% during that period while stretching the period over a month that increases to 4.18%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 63.79 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Morgan Stanley which upgraded the stock as “Overweight” in its note to investors issued on March 01, 2023, recommending a price target of between $141 and $187 for it. UBS also issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $100 and $158.
Over the week, SRPT’s stock price is moving 0.83% up while it is 24.35% when we observe its performance for the past one month. Year-to-date it is 15.50% up and over the past year, the stock is showing an upside performance of 96.49%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2022, when its quarterly earnings per share (EPS) of -$1.24 beat the consensus estimate of -$1.35 for the same. The company is expected to be releasing its next quarterly report in 05/03/2023, for which analysts forecasted an EPS of -$1.45 while estimate for next year EPS is -$4.96. For SRPT, analysts are forecasting an EPS-growth rate of 38.20% for current year and estimate for EPS growth in next year is 196.80%. In next quarter, company is expected to be making quarterly sales of $259.83 million as analysts are expecting the sales for current fiscal year at $1.22 billion and seeing the company making $2.23 billion in sales next year. Moreover, analysts are in estimates of $243.86 million for current-quarter revenue.
Currently, Sarepta Therapeutics Inc.’s total number of outstanding shares is 87.84M with 4.39% of that held by the insiders while 90.21% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -35.10% and return on equity (ROE) at -117.30%. It has a 31.19 of forward P/E ratio. Stock’s beta reads 0.98. Stock has a price to book (P/B) ratio of 34.17 while price to sale or P/S ratio amounts to 14.56. Its return on asset (ROA) is -22.80% on average.
A filing at the U.S. Securities and Exchange Commission revealed that Vanguard Total Stock Market Index came shrinking its share ownership by 0.74% in the Sarepta Therapeutics Inc. (SRPT) increasing its stake to 2.91% with control over 18903.0 shares in the company. In the most recent quarter, Vanguard Small Cap Index Fund came rising its stake by 0.55% in the company and now holds 2.16 million or 2.46% of the company’s stake having worth of about 263.86 million.
Leave a Reply